AU2003296596B2 - Halothenoyl-cyclopropane-1-carboxylic acid derivatives - Google Patents

Halothenoyl-cyclopropane-1-carboxylic acid derivatives Download PDF

Info

Publication number
AU2003296596B2
AU2003296596B2 AU2003296596A AU2003296596A AU2003296596B2 AU 2003296596 B2 AU2003296596 B2 AU 2003296596B2 AU 2003296596 A AU2003296596 A AU 2003296596A AU 2003296596 A AU2003296596 A AU 2003296596A AU 2003296596 B2 AU2003296596 B2 AU 2003296596B2
Authority
AU
Australia
Prior art keywords
cyclopropane
thenoyl
chloro
carboxylate
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003296596A
Other languages
English (en)
Other versions
AU2003296596A1 (en
Inventor
Luca Benatti
Carla Caccia
Ruggero Fariello
Roberto Pellicciari
Patricia Salvati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newron Pharmaceuticals SpA
Original Assignee
Newron Pharmaceuticals SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharmaceuticals SpA filed Critical Newron Pharmaceuticals SpA
Publication of AU2003296596A1 publication Critical patent/AU2003296596A1/en
Application granted granted Critical
Publication of AU2003296596B2 publication Critical patent/AU2003296596B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2003296596A 2002-11-28 2003-11-25 Halothenoyl-cyclopropane-1-carboxylic acid derivatives Ceased AU2003296596B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02026597A EP1424333A1 (en) 2002-11-28 2002-11-28 Halothenoyl-cyclopropane-1-carboxylic acid derivatives
EP02026597.1 2002-11-28
PCT/EP2003/013244 WO2004048361A1 (en) 2002-11-28 2003-11-25 Halothenoyl-cyclopropane-1-carboxylic acid derivatives

Publications (2)

Publication Number Publication Date
AU2003296596A1 AU2003296596A1 (en) 2004-06-18
AU2003296596B2 true AU2003296596B2 (en) 2010-03-04

Family

ID=32241303

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003296596A Ceased AU2003296596B2 (en) 2002-11-28 2003-11-25 Halothenoyl-cyclopropane-1-carboxylic acid derivatives

Country Status (13)

Country Link
US (1) US20060116329A1 (enExample)
EP (2) EP1424333A1 (enExample)
JP (1) JP4522864B2 (enExample)
AT (1) ATE361921T1 (enExample)
AU (1) AU2003296596B2 (enExample)
CA (1) CA2507597A1 (enExample)
CY (1) CY1106692T1 (enExample)
DE (1) DE60313798T2 (enExample)
DK (1) DK1565451T3 (enExample)
ES (1) ES2286509T3 (enExample)
PT (1) PT1565451E (enExample)
SI (1) SI1565451T1 (enExample)
WO (1) WO2004048361A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1475088A1 (en) * 2003-05-05 2004-11-10 Newron Pharmaceuticals S.p.A. Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
GB2402940A (en) * 2004-08-19 2004-12-22 Pfizer Ltd Biomarkers of inflammation and/or macrophage activation
JP2008535892A (ja) * 2005-04-11 2008-09-04 プロビオドルグ エージー プロリルエンドペプチダーゼの阻害剤
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
JP6275690B2 (ja) * 2012-04-05 2018-02-07 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
JP6449893B2 (ja) * 2013-09-26 2019-01-09 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法
JP2016536350A (ja) 2013-09-26 2016-11-24 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法
GB201322512D0 (en) 2013-12-19 2014-02-05 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201508857D0 (en) 2015-05-22 2015-07-01 Glaxosmithkline Ip Dev Ltd Compounds
GB201508864D0 (en) 2015-05-22 2015-07-01 Glaxosmithkline Ip Dev Ltd Compounds
PL450605A1 (pl) 2024-12-16 2026-06-22 Uniwersytet Łódzki Zastosowanie inhibitorów enzymów szlaku kynureninowego jako regulatora wzrostu Trichophyton rubrum do zapobiegania lub leczenia grzybic, zwłaszcza wywołanych Trichophyton rubrum

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278435B (de) * 1965-01-19 1968-09-26 Merck Ag E Verfahren zur Herstellung von 1, 2-disubstituierten Cyclopropanderivaten
US4022903A (en) * 1975-06-05 1977-05-10 Abbott Laboratories α-Thienyl and α-substituted thienyl, phenyl and substituted phenyl cyclopropylomethanols useful as biodegradable insecticides and mollusicides
US6274590B1 (en) * 1993-01-15 2001-08-14 G. D. Searle & Co. Method of treating skin related conditions
JP4176150B2 (ja) * 1996-10-30 2008-11-05 塩野義製薬株式会社 グルタミン酸放出阻害剤および新規化合物
GB9705031D0 (en) * 1997-03-11 1997-04-30 Pharmacia & Upjohn Spa 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives

Also Published As

Publication number Publication date
JP4522864B2 (ja) 2010-08-11
WO2004048361A1 (en) 2004-06-10
CY1106692T1 (el) 2012-05-23
DK1565451T3 (da) 2007-09-10
JP2006509753A (ja) 2006-03-23
DE60313798D1 (en) 2007-06-21
US20060116329A1 (en) 2006-06-01
PT1565451E (pt) 2007-08-03
CA2507597A1 (en) 2004-06-10
ES2286509T3 (es) 2007-12-01
EP1565451B1 (en) 2007-05-09
SI1565451T1 (sl) 2007-08-31
DE60313798T2 (de) 2008-01-24
ATE361921T1 (de) 2007-06-15
AU2003296596A1 (en) 2004-06-18
EP1565451A1 (en) 2005-08-24
EP1424333A1 (en) 2004-06-02

Similar Documents

Publication Publication Date Title
AU623900B2 (en) Novel hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
EP2041072B1 (en) Cxcr2 antagonists
JPWO2002016311A1 (ja) カルボン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
FR2576901A1 (fr) Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique
EP1565451B1 (en) Halothienoyl-cyclopropane-1-carboxylic acid derivatives
CN101146763A (zh) 胰高血糖素受体拮抗剂化合物、含有这种化合物的组合物以及使用方法
KR20250136942A (ko) Cftr 조절용 화합물, 조성물, 및 방법
US8653299B2 (en) Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
ES2228587T3 (es) Retinoides para el tratamiento de enfisema.
US9938252B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2009269842B2 (en) Use of indole derivatives as NURR-1 activators for treating Parkinson's disease
JP2023530708A (ja) 甲状腺様作用剤
KR0153527B1 (ko) 아릴설폰아미드 및 이를 함유하는 약제학적 조성물
US6506780B2 (en) Benzophenones and sulfones as inhibitors of glycine uptake
KR101179840B1 (ko) 치환 또는 무치환 아미노기를 도입한 4-피리딜알킬티오기를갖는 신규 고리형 화합물
JP2005527518A (ja) 新規なカルコン（ｃｈａｌｃｏｎｅ）誘導体とその使用
EP1475385A1 (en) Glycoside derivatives of 2-(3,4-dichlorobenzoyl)-cycopropane-1-carboxylic acid
US8980938B2 (en) CXCR2 inhibitors
IL286149B1 (en) Caspase inhibitors and methods of use thereof
EP0749957B1 (en) Aromatic hydroxamic acid compounds, their production and use
FR2849849A1 (fr) Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
USRE37078E1 (en) Thiophene compounds
JPH10231285A (ja) フタルイミド誘導体又はその塩、それらの製造方法及びそれらを含有する医薬組成物
US20150018411A1 (en) Compounds as ppar beta/delta inhibitors for treating ppar beta/delta-mediated diseases
JP2002371033A (ja) ω−アリール−α−置換脂肪酸誘導体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired